BACKGROUND: The expression of human endogenous retrovirus (HERV) mRNA and proteins was associated recently with diseases that include human malignancies. The authors report that, in the current study, transcripts encoding the envelope region of an HERV family, HERV-E, were expressed in human prostate carcinoma. METHODS: RNA was isolated from various prostate tissues and was tested for the expression of various HERV envelope (env) genes by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, RNA in situ hybridization (ISH), and Northern blot analysis. Variants of HERV that appeared in prostate carcinoma tissues were sequenced, and HERV-E was expressed in prokaryotic and eukaryotic systems. RESULTS: In the current study, the authors found that the mRNA of the env gene of one particular family of HERVs, HERV-E, was expressed in some prostate carcinoma tissues (38.8% positive; n = 49 specimens) but not in normal prostate tissues using RT-PCR, RNA ISH, and Northern blot assays. The expression of HERV-E transcripts in prostate tumor epithelial cells was confirmed further by ISH using an HERV-E specific antisense probe. Approximately 50% of the cDNA of HERV-E obtained from prostate carcinoma specimens contained no stop codon and expressed proteins in prokaryotic or eukaryotic expression systems. Furthermore, the expression of both HERV-E and ERV3 (another class of HERV) was detected in the same prostate carcinoma tissues. CONCLUSIONS: The expression and distribution of multiple HERV-E endogenous retroviral elements in prostate carcinoma, but not in normal control specimens, suggests that they may serve as novel tumor markers for the early diagnosis and immunotherapy of patients with prostate carcinoma. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11451
BACKGROUND: The expression of human endogenous retrovirus (HERV) mRNA and proteins was associated recently with diseases that include humanmalignancies. The authors report that, in the current study, transcripts encoding the envelope region of an HERV family, HERV-E, were expressed in humanprostate carcinoma. METHODS: RNA was isolated from various prostate tissues and was tested for the expression of various HERV envelope (env) genes by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, RNA in situ hybridization (ISH), and Northern blot analysis. Variants of HERV that appeared in prostate carcinoma tissues were sequenced, and HERV-E was expressed in prokaryotic and eukaryotic systems. RESULTS: In the current study, the authors found that the mRNA of the env gene of one particular family of HERVs, HERV-E, was expressed in some prostate carcinoma tissues (38.8% positive; n = 49 specimens) but not in normal prostate tissues using RT-PCR, RNA ISH, and Northern blot assays. The expression of HERV-E transcripts in prostate tumor epithelial cells was confirmed further by ISH using an HERV-E specific antisense probe. Approximately 50% of the cDNA of HERV-E obtained from prostate carcinoma specimens contained no stop codon and expressed proteins in prokaryotic or eukaryotic expression systems. Furthermore, the expression of both HERV-E and ERV3 (another class of HERV) was detected in the same prostate carcinoma tissues. CONCLUSIONS: The expression and distribution of multiple HERV-E endogenous retroviral elements in prostate carcinoma, but not in normal control specimens, suggests that they may serve as novel tumor markers for the early diagnosis and immunotherapy of patients with prostate carcinoma. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11451
Authors: Christof C Smith; Kathryn E Beckermann; Dante S Bortone; Aguirre A De Cubas; Lisa M Bixby; Samuel J Lee; Anshuman Panda; Shridar Ganesan; Gyan Bhanot; Eric M Wallen; Matthew I Milowsky; William Y Kim; W Kimryn Rathmell; Ronald Swanstrom; Joel S Parker; Jonathan S Serody; Sara R Selitsky; Benjamin G Vincent Journal: J Clin Invest Date: 2018-10-02 Impact factor: 14.808
Authors: Berna Uygur; Evgenia Leikina; Kamran Melikov; Rafael Villasmil; Santosh K Verma; Calvin P H Vary; Leonid V Chernomordik Journal: Mol Cancer Res Date: 2018-12-26 Impact factor: 5.852
Authors: Elena Cherkasova; Claire Scrivani; Susan Doh; Quinn Weisman; Yoshiyuki Takahashi; Nanae Harashima; Hisayuki Yokoyama; Ramaprasad Srinivasan; W Marston Linehan; Michael I Lerman; Richard W Childs Journal: Cancer Res Date: 2016-02-09 Impact factor: 12.701
Authors: Yoshiyuki Takahashi; Nanae Harashima; Sachiko Kajigaya; Hisayuki Yokoyama; Elena Cherkasova; J Philip McCoy; Ken-Ichi Hanada; Othon Mena; Roger Kurlander; Abdul Tawab; Tawab Abdul; Ramaprasad Srinivasan; Andreas Lundqvist; Elizabeth Malinzak; Nancy Geller; Michael I Lerman; Richard W Childs Journal: J Clin Invest Date: 2008-03 Impact factor: 14.808
Authors: Sebastian Szpakowski; Xueguang Sun; José M Lage; Andrew Dyer; Jill Rubinstein; Diane Kowalski; Clarence Sasaki; Jose Costa; Paul M Lizardi Journal: Gene Date: 2009-08-21 Impact factor: 3.688
Authors: Feng Wang-Johanning; Ming Li; Francisco J Esteva; Kenneth R Hess; Bingnan Yin; Kiera Rycaj; Joshua B Plummer; Jeremy G Garza; Stefan Ambs; Gary L Johanning Journal: Int J Cancer Date: 2013-09-13 Impact factor: 7.396